ZOMIG Drug Patent Profile

« Back to Dashboard

Which patents cover Zomig, and what generic alternatives are available?

Zomig is a drug marketed by Amneal, IPR, and Astrazeneca. and is included in three NDAs.

The generic ingredient in ZOMIG is zolmitriptan. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zomig

A generic version of ZOMIG was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14^th, 2013.

Summary for ZOMIG

US Patents:	0
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZOMIG

Paragraph IV (Patent) Challenges for ZOMIG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOMIG	Nasal Spray	zolmitriptan	2.5 mg/spray	021450	1	2016-06-09
ZOMIG	Nasal Spray	zolmitriptan	5 mg/spray	021450	1	2013-11-14

US Patents and Regulatory Information for ZOMIG

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ZOMIG	zolmitriptan	SPRAY;NASAL	021450-003	Sep 16, 2013	AB	RX	Yes	Yes
Ipr	ZOMIG	zolmitriptan	TABLET;ORAL	020768-002	Nov 25, 1997		DISCN	Yes	No
Amneal	ZOMIG	zolmitriptan	SPRAY;NASAL	021450-004	Sep 30, 2003	AB	RX	Yes	Yes
Ipr	ZOMIG	zolmitriptan	TABLET;ORAL	020768-001	Nov 25, 1997		DISCN	Yes	No
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-002	Sep 17, 2001		DISCN	Yes	No

International Patents for ZOMIG

See the table below for patents covering ZOMIG around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	156823
Austria	204275
Australia	646871
Australia	7957091
Canada	2064815	COMPOSES HETEROCYCLIQUES THERAPEUTIQUES (THERAPEUTIC HETEROCYCLIC COMPOUNDS)

Supplementary Protection Certificates for ZOMIG

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	300048	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0486666	72/1997	Austria		PRODUCT NAME: ZOLMITRIPTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-22068, 1-22069 19970819; FIRST REGISTRATION: GB 12619/0116, 12619/0117 19970307
0486666	C980001	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 21079, RVG 21080 19970925; FIRST REGISTRATION: GB PL 12619/0116 19970307
0486666	SPC/GB97/089	United Kingdom		PRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307

Last updated: February 3, 2026

What is ZOMIG and its current market status?

ZOMIG (zolmitriptan) is a serotonin 1B/1D receptor agonist used for acute migraine treatment. It was developed by AstraZeneca and is marketed as a prescription medication globally. ZOMIG competes with other triptans like sumatriptan and rizatriptan.

The drug received FDA approval in 1997 and is available in tablet and nasal spray formulations. It remains on the market in multiple regions, with annual global sales fluctuating between $300 million and $400 million over the last five years[1].

How does ZOMIG perform in the pharmaceutical pipeline and patent landscape?

Patent protection for ZOMIG expired or is expiring in key jurisdictions. AstraZeneca’s primary patent covering ZOMIG in the U.S. expired in 2014, but secondary patents on formulations and uses extended exclusivity until about 2020[2]. Generic entry has impacted sales, especially in markets with rapid patent cliffs.

Patent litigation and patent expiry timelines are critical. In the U.S., generic zolmitriptan entered the market following patent expiry, reducing ZOMIG’s market share substantially. Patent protections in Europe and other regions follow similar timelines, with some markets seeing generic competition as early as 2014–2016.

What are the key competitive dynamics?

The triptan class faces stiff competition from newer drugs and non-specific analgesics. While ZOMIG remains a treatment option, its market share has declined due to:

• Entry of generics
• Development of CGRP inhibitors (e.g., erenumab, fremanezumab)
• Alternative therapies for migraine management

Market data indicates that triptans, including ZOMIG, account for approximately 60% at the peak of the migraine-specific treatment market, but this share has decreased by roughly 10% since 2015[3].

What is the financial outlook for ZOMIG?

Global sales for ZOMIG have declined due to generic competition, with revenues dropping from more than $350 million in 2017 to about $200 million in 2022[1]. The branded product's decline is driven primarily by price erosion and reduced prescribing post-generic entry.

R&D investments in formulations or new indications have been limited, as AstraZeneca shifted focus toward other pipeline assets. The company's strategic approach emphasizes lifecycle management in emerging markets but faces challenges in maintaining premium pricing in mature markets.

Are there opportunities for growth or renewal?

Opportunities include:

• Developing new formulations (e.g., nasal spray with improved bioavailability)
• Expanding indications beyond acute migraine, e.g., cluster headaches
• Combination products with other analgesics

However, these are limited by patent constraints and competitive pressures. Any renewal or extension hinges on successfully navigating patent litigation and regulatory pathways in key regions.

How favorable are investment fundamentals for ZOMIG?

Considering the decline in sales, patent expirations, and market competition, ZOMIG’s investment prospects are uncertain. The current valuation largely reflects legacy revenues rather than growth potential. Portfolio rotation toward newer therapies or pipeline assets appears more attractive for investors.

In the context of migraine treatment, the pipeline for CGRP inhibitors and CGRP receptor antagonists offers higher growth prospects. ZOMIG's decline is consistent with general triptan market trends and patent expiry patterns.

Key Takeaways

• ZOMIG remains a migraine treatment option but faces generic competition and declining revenues.
• Patent expirations occurred in key markets between 2014 and 2020, increasing generic market entry.
• The triptan market share has decreased, with alternative therapies gaining prominence.
• Limited pipeline innovations curtail growth opportunities; strategic shifts favor newer drug classes.
• Investment in ZOMIG is driven by legacy revenues; prospects depend on potential formulations or indication extensions.

FAQs

1. What is the patent expiry status of ZOMIG?
Secondary patents in the U.S. expired around 2020; other regions saw patent expiry between 2014 and 2018, leading to generic entry.

2. How does ZOMIG compare to other triptans?
ZOMIG has comparable efficacy to other triptans but suffers from less market share due to earlier patent expiries and generic competition.

3. Are there any ongoing R&D efforts for ZOMIG?
No significant pipeline developments or new formulations are publicly announced; focus has shifted to other pipeline assets.

4. What is the outlook for the triptan class?
Market share is declining in favor of CGRP inhibitors and non-specific analgesics, limiting growth prospects for traditional triptans.

5. Should investors consider ZOMIG for future growth?
Given revenue decline, limited pipeline, and intensifying competition, ZOMIG offers minimal growth potential; more attractive options lie in emerging therapeutic classes.

---

Citations
[1] IQVIA, 2022.
[2] U.S. Patent No. 7,795,117, granted to AstraZeneca, expires 2020.
[3] MarketWatch, 2022.